Home > Drugs A – Z > Moxifloxacin (By mouth)
  • We are sorry, but NCBI web applications do not support your browser and may not function properly. More information

Moxifloxacin (By mouth)

This medicine is a quinolone antibiotic that treats infections.

What works?

Learn more about the effects of these drugs. The most reliable research is summed up for you in our featured article.

Moxifloxacin is used to treat bacterial infections in many different parts of the body. Moxifloxacin belongs to the class of medicines known as quinolone antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections. This medicine is available only with your doctor's prescription… Read more
Brand names include
Avelox
Other forms
Injection, Into the eye
Drug classes About this
Antibiotic

What works? Research summarized

Evidence reviews

Moxifloxacin versus levofloxacin for acute exacerbation of chronic obstructive pulmonary diseases: a systematic review

Bibliographic details: Wang XH, Liu XJ.  Moxifloxacin versus levofloxacin for acute exacerbation of chronic obstructive pulmonary diseases: a systematic review. Chinese Journal of Evidence-Based Medicine 2012; 12(6): 694-699 Available from: http://www.cjebm.org.cn/oa/DArticle.aspx?type=view&id=201206014

A meta analysis of the efficacy and safety of moxifloxacin in Chinese patients with multi-drug resistant pulmonary tuberculosis

Bibliographic details: Liu S, Chen S, Ren X, Zhang G.  A meta analysis of the efficacy and safety of moxifloxacin in Chinese patients with multi-drug resistant pulmonary tuberculosis. African Journal of Pharmacy and Pharmacology 2012; 6(1): 57-65 Available from: http://www.academicjournals.org/journal/AJPP/article-abstract/D50963D31352

Efficacy and safety of moxifloxacin for treating complicated intra-abdominal infections: a meta-analysis

Bibliographic details: Xi Q, Hu YF, Zheng XC.  Efficacy and safety of moxifloxacin for treating complicated intra-abdominal infections: a meta-analysis. Chinese Journal of New Drugs 2013; 22(2): 210-214 Available from: http://116.228.189.110/kns50/detail.aspx?dbname=CHKJ2013&filename=ZXYZ201302015&filetitle=%E8%8E%AB%E8%A5%BF%E6%B2%99%E6%98%9F%E6%B2%BB%E7%96%97%E5%A4%8D%E6%9D%82%E8%85%B9%E8%85%94%E6%84%9F%E6%9F%93%E7%9A%84%E7%96%97%E6%95%88%E5%92%8C%E5%AE%89%E5%85%A8%E6%80%A7%E7%9A%84Meta%E5%88%86%E6%9E%90

See all (27)

Summaries for consumers

Preventative antibiotic therapy for people with COPD

COPD is a common chronic respiratory disease mainly affecting people who smoke now or have done so previously. It could become the third leading cause of death worldwide by 2030. People with COPD experience gradually worsening shortness of breath and cough with sputum because of permanent damage to their airways and lungs. Those with COPD may have flare‐ups (or exacerbations) that usually occur after respiratory infections. Exacerbations may lead to further irreversible loss of lung function with days off work, hospital admission, reduction in quality of life and they may even cause death.

Substituting or adding fluoroquinolones to established first‐line antituberculous drug regimens gives no additional benefit or risks

Tuberculosis is an infectious disease caused by Mycobacterium tuberculosis bacteria. Over two billion people worldwide are believed to be latently infected with TB and approximately 10% of these people will develop active TB later in life. The World Health Organization currently only recommend treatment with fluoroquinolones for patients who cannot take standard first‐line drugs. In this review, we examined the effect of including fluoroquinolones in first‐line treatment regimens on people with presumed drug‐sensitive tuberculosis.

The rapid test GenoType® MTBDRsl for testing resistance to second‐line TB drugs

Different drugs are available to treat people with tuberculosis (TB), but resistance to these drugs is a growing problem. People with drug‐resistant TB are more likely to die than people with drug‐susceptible TB. People with drug‐resistant TB require "second‐line" TB drugs that, compared with "first‐line" TB drugs used to treat drug‐susceptible TB, cause more side effects and must be taken for longer. Extensively drug‐resistant TB (XDR‐TB) is a type of TB that is resistant to almost all TB drugs. A rapid and accurate test could identify people with drug‐resistant TB, likely improve patient care, and reduce the spread of drug‐resistant TB.

See all (4)

PubMed Health Blog...

read all...